Clinical trials and dipyridamole formulation selection.
Derendorf
Hartmut
H
D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D020766:Intracranial Embolism / Q000150:complications; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012008:Recurrence; D012107:Research Design; D020521:Stroke / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin